Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
05/2003
05/20/2003US6566491 Cyclopeptide derivatives
05/20/2003US6566394 Useful as anti-inflammatory agents and immunosuppressive agents
05/20/2003US6566387 For therapy of psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock
05/20/2003US6566376 Diphenyl-piperidine derivative
05/20/2003US6566366 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
05/20/2003US6566363 5-amino-3-substituted-pyrazolo(4,5-d)thiazole compounds that mediate and/or inhibit the activity of cyclin-dependent kinases, useful for treating cancer, angiogenesis and cellular proliferation
05/20/2003US6566357 Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
05/20/2003US6566338 Administering caspase inhibitor for therapy of oral mucositis, gastrointestinal mucositis, bladder mucositis or proctitis resulting from chemotherapy or radiation therapy of cancer in an animal
05/20/2003US6566328 Administering to the patient a therapeutically effective amount of a polypeptide for therapy of patient in need of agonist effect of human growth hormone
05/20/2003US6565880 Antiinflammatory agents
05/20/2003US6565848 Cadherin-like asymmetry protein-1, and methods for its use
05/15/2003WO2003040399A2 Therapeutic methods for nucleic acid delivery vehicles
05/15/2003WO2003040371A1 Novel g protein-coupled receptor protein and dna thereof
05/15/2003WO2003040366A2 Inhibitor oligonucleotides and their use for specific repression of a gene
05/15/2003WO2003040358A1 Somatic cell derived embryonic stem cells and its differentiated cells
05/15/2003WO2003040345A2 Type 2 cytokine receptor and nucleic acids encoding same
05/15/2003WO2003040329A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003WO2003040296A2 Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis
05/15/2003WO2003040188A1 Antibody stimulating il-1ra production
05/15/2003WO2003040144A2 Heterocyclic compound based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
05/15/2003WO2003040143A1 Amine salts of an integrin receptor antagonist
05/15/2003WO2003040134A1 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof
05/15/2003WO2003040115A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003WO2003040113A1 3-amido-1,2-benzoisoxazole derivatives, process for preparation, and use thereof
05/15/2003WO2003040110A1 Triazole derivatives as cyclooxygenase (cox) inhibitors
05/15/2003WO2003040107A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
05/15/2003WO2003040102A1 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors
05/15/2003WO2003040101A1 Anthranilic acid amides and pharmaceutical use thereof
05/15/2003WO2003040099A1 Preparation of benzosuberonylpiperidine compounds
05/15/2003WO2003040098A1 Novel metalloproteinase inhibitors
05/15/2003WO2003040080A2 Lipoxin a4 analogs
05/15/2003WO2003039580A1 Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
05/15/2003WO2003039574A1 Endophilin homologous proteins involved in the regulation of energy homeostasis
05/15/2003WO2003039572A1 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
05/15/2003WO2003039564A1 Selective targeting of apoptotic cells
05/15/2003WO2003039552A1 Combination of pde4 or pde3/4 inhibitor and an anti-rheumatic drug
05/15/2003WO2003039548A1 Hydrazono-malonitriles
05/15/2003WO2003039544A1 Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
05/15/2003WO2003039534A1 Compositions and methods for treating osteoporosis
05/15/2003WO2003039523A2 OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
05/15/2003WO2003039473A2 Method for treating or preventing inflammatory diseases
05/15/2003WO2003039472A2 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003WO2003039452A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003WO2003039451A2 Thiazole pyridazinones as adenosine antagonists
05/15/2003WO2003039446A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
05/15/2003WO2003039231A2 Compounds and methods for treating transplant rejection
05/15/2003WO2003039225A2 Antigen arrays comprising rankl for treatment of bone disease
05/15/2003WO2002097032A3 Proteins associated with cell growth, differentiation, and death
05/15/2003WO2002083926A3 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
05/15/2003WO2002068056A3 Combination comprising a 1,4-dioxonaphathalene compound and ribenoside
05/15/2003WO2002058679A3 Antiangiogenic compounds and an assay for inhibitors of cell invasion
05/15/2003WO2002057298A3 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
05/15/2003WO2002040016A8 Association of calpain inhibitors and reactive oxygen species trapping agents
05/15/2003WO2002026781A9 Ige receptor antagonists
05/15/2003WO2002026717A8 Hydroxy acid integrin antagonists
05/15/2003WO2002000611A8 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
05/15/2003WO2001079173A3 Enamine derivatives as cell adhesion molecules
05/15/2003US20030092917 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors
05/15/2003US20030092908 Autoimmune diseases; rheumatic diseases; multiple sclerosis; inflammatory bowel disease; immunosuppressants
05/15/2003US20030092800 Sustained release; drug delivery
05/15/2003US20030092771 Inhibitors of transcription factor NF-kappaB
05/15/2003US20030092748 Benzenesulfonamide derivatives and their use as MEK inhibitors
05/15/2003US20030092736 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
05/15/2003US20030092732 Eating disorders; dietetics; antiinflammatory agents; autoimmune diseases
05/15/2003US20030092728 Antagonists of MCP-1 function and methods of use thereof
05/15/2003US20030092727 Hydroxamic and carboxylic acid derivatives
05/15/2003US20030092721 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092717 Inhibitors of p38 kinase
05/15/2003US20030092714 Heterocyclic inhibitors of ERK2 and uses thereof
05/15/2003US20030092713 Antiinflammatory agents; antiallergens; psychological disorders
05/15/2003US20030092712 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092706 Mixtures of phosphodiesterase inhibitor and antiarthritic agents; bioavailability, side effect reduction
05/15/2003US20030092704 Novel arylglycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds
05/15/2003US20030092703 Caspase inhibitors and uses thereof
05/15/2003US20030092702 Antiinflammatory agents; autoimmune disease; autoimmune diseases
05/15/2003US20030092697 Antidiabetic, antilipemic agents; cardiovascular disorders; anticancer agents
05/15/2003US20030092686 Calibrating therapy dosage
05/15/2003US20030092678 Muscle relaxants, controlling immunology, sexual disorders, rheumatic diseases
05/15/2003US20030092633 Preventing desensitization of receptors
05/15/2003US20030092630 Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases
05/15/2003US20030092607 A stable antibody liquid comprising a precipitated immunoglobulins and water; precipitating with a biocompatible polymer; storage stability
05/15/2003US20030092601 Microcompetition and human disease
05/15/2003US20030092163 Probiotic bifidobacterium strains
05/15/2003US20030092059 Human antibodies that bind human TNFalpha
05/15/2003US20030092044 Nucleotide sequences coding polypeptide for use in the treatment of apoptosis, inflammatory and autoimmune disorders
05/15/2003US20030092025 Nucleotide sequences coding polypeptides for use in the diagnosis, treatment, prevention of tumor disorders
05/15/2003US20030091974 Detecting compounds capable of exhausting mast cells; culture mast cells, incubate with modulator, measure mast cell death, classify compound
05/15/2003US20030091973 Method of identifying osteoregenerative agents using differential gene expression
05/15/2003US20030091669 Mixture saponin, sugars and protein; solvent extraction, drying, sterilization; brain disorders, Alzheimer's disease
05/15/2003US20030091659 Plant extracts; active materials
05/15/2003US20030091620 Transdermal drug delivery systems containing quaternary ammonium salts and methods of using the same
05/15/2003US20030091611 Antiproliferative agents ; antiinflammatory agents; insertable stent
05/15/2003US20030091583 Use of mia in immunotheraphy
05/15/2003US20030091549 Antiinflammatory agents; inflammatory bowel disease; gastrointestinal disorders
05/15/2003CA2789407A1 Inhibitor oligonucleotides and their use for specific repression of a gene
05/15/2003CA2669810A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003CA2467853A1 Antibody stimulating il-1ra production
05/15/2003CA2466303A1 Selective targeting of apoptotic cells
05/15/2003CA2466198A1 Somatic cell derived embryonic stem cells and their differentiated progenies
05/15/2003CA2466030A1 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
1 ... 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 ... 820